Ruth Brenk
Professor, Head of research of the Department of Biomedicine
- E-mailRuth.Brenk@uib.no
- Phone+47 55 58 60 70
- Visitor AddressJonas Lies vei 915009 BergenRoom5A125B
- Postal AddressPostboks 78045020 Bergen
Our overall research goal is to improve methods used for structure-based drug design and to apply these methods to design inhibitors for enzymes with biological relevance. A key point in our research is the interplay of theoretical and experimental methods.
To read more about what we do, check out our homepage .
For a full list of publications click here.
Academic article
- (2022). Fragment screening using biolayer interferometry reveals ligands targeting the SHP-motif binding site of the AAA+ ATPase p97. Communications chemistry.
- (2022). Crystal structure of Pseudomonas aeruginosa FabB C161A, a template for structure-based design for new antibiotics. F1000 Research.
- (2021). DrugPred_RNA—A Tool for Structure-Based Druggability Predictions for RNA Binding Sites. Journal of Chemical Information and Modeling. 4068-4081.
- (2021). An Experimental Toolbox for Structure-Based Hit Discovery for P. aeruginosa FabF, a Promising Target for Antibiotics . ChemMedChem. 2715.
- (2020). Targeting the Class A Carbapenemase GES-5 via Virtual Screening. Biomolecules.
- (2019). Identification of a potential allosteric site of Golgi α-mannosidase II using computer-aided drug design. PLOS ONE. 1-19.
- (2019). How To Design Selective Ligands for Highly Conserved Binding Sites: A Case Study Using N-Myristoyltransferases as a Model System. Journal of Medicinal Chemistry.
- (2018). In silico identification and experimental validation of hits active against KPC-2 β-lactamase. PLOS ONE.
- (2015). To hit or not to hit, that is the question -genome-wide structure-based druggability predictions for pseudomonas aeruginosa proteins. PLOS ONE.
Academic lecture
- (2022). TARGETING A PSEUDOMONAS AERUGINOSA β-KETOACYL-(ACYL-CARRIER-PROTEIN) SYNTHASE WITH COVALENT INHIBITORS INSPIRED BY CERULENIN.
- (2022). Hit discovery for RNA ligands.
- (2022). Hit Discovery for riboswitches as targets for antibiotics.
- (2021). Targeting Bacterial Fatty Acid Synthesis using Fragment-Based Drug Design.
- (2021). Structure-based ligand design for protein and RNA targets for new antibiotics.
- (2021). Structure-based ligand design for protein and RNA targets for new antibiotics.
- (2021). Structure-based ligand design for protein and RNA targets for new antibiotics.
Masters thesis
- (2021). The Search for Antibiotic Leads: Targeting Pantothenate Kinase in Pseudomonas aeruginosa.
- (2021). Structure-based drug design of β-ketoacyl-[acyl carrier protein] synthase I (FabB) inhibitors as lead structures for new antibiotics.
- (2020). Structure-based design of pantothenate kinase inhibitors as lead structures for new antibiotics.
Poster
- (2022). Structure-based hit discovery for riboswitch ligands.
- (2022). A P. AERUGINOSA FATTY ACID SYNTHESIS PROTEIN CRYSTALLOGRAPHIC FRAGMENT SCREEN AND ATTEMPTED OPTIMIZATION OF A HIT.
Academic literature review
- (2021). Riboswitches as Drug Targets for Antibiotics. Antibiotics. 1-22.
- (2021). Fragment-Based Drug Discovery for RNA Targets. ChemMedChem.
- (2017). Ligand design for riboswitches, an emerging target class for novel antibiotics. Future Medicinal Chemistry. 1649-1662.
Chapter
- (2017). Structure-Based Discovery of Small Molecules Binding to RNA. . In:
- (2017). RNA Therapeutics. Springer.
More information in national current research information system (CRIStin)
Fields of competence
